Evonik opens new biosurfactant plant in Slovakia
Evonik officially inaugurates its new sustainable biosurfactant plant together with key customers in Slovakia.
The plant represents an investment of several hundred million euros and is the first worldwide to produce rhamnolipid biosurfactants on a large scale. These extremely high-quality, sustainable biosurfactants are already transforming the cleaning, beauty and personal care industries and have great potential in many other applications.
"We go above and beyond to create completely new solutions that drive sustainable transformation in multiple industries. Our leadership, based on systems thinking and a shared vision with our customers, makes this scalable action possible," said Christian Kullmann, CEO of Evonik.
Evonik has been leading the development of biosurfactants on an industrial scale with its IP-protected fermentation-based rhamnolipid production process. Rhamnolipids are produced from renewable corn raw materials using a biotechnological process. This results in a high-performance, non-toxic, biodegradable biosurfactant. Rhamnolipids are in growing demand as they offer a sustainable alternative to surfactants based on fossil sources or tropical oils.
By 2030, Evonik plans to invest more than 3 billion euros in next-generation solutions - products with outstanding sustainability benefits. An example is the biosurfactant technology platform that Evonik is building to serve different industries.
The Nutrition & Care business of Evonik's Life Science division is a leader in the field of biotechnology. Driven by sustainable development, the division is using innovative biosolutions to address the challenges of biocycle care through closed-loop carbon systems while maintaining high functionality and protecting biodiversity. In addition to biosurfactants, the biosolutions of the Nutrition & Care business also include biotech actives, cell culture solutions and nucleic acid-based pharmaceuticals.
The new plant is located at Evonik Fermas, the company's site in Slovenská Ľupča, Slovakia. The biotech competences of the site have been accumulated over decades, making it a logical choice for the first industrial-scale rhamnolipid production plant. This consolidates Evonik Fermas' position as Evonik's biotech scale-up and launch platform.
Merck to acquire EyeBio for $3 billion
2026-10-17
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
BASF and Evonik Rumored Potential Acquisition or Merger
-
Evonik Expands Slovakian Fermas Site with €80 Million Investment to Boost Pharmaceutical CDMO Capacity
-
Evonik to Close Two German Plants, Further Cutting Europe’s High-Purity Silicon Tetrachloride Capacity
-
Multiple Chemical Industry Leaders Post Strong H1 Earnings Growth as Sector Profitability Revives
-
Evonik Inaugurates New Speciality Alumina Plant in Japan, Bolstering Regional Growth Strategy
-
Evonik and AMSilk Expand Collaboration to Develop Sustainable Biotech Silk Materials
-
Evonik Launches Asia’s First Alkoxide Plant in Jurong Island
-
Evonik Converts Epoxy Hardener Production to 100% Renewable Electricity
-
Breakup! Vland Biotech and Evonik Part Ways as GHS Joint Venture Falls Short of Expectations
-
Evonik Completes Shift to Green Electricity for Polybutadiene Production at its Marl, Germany, Plant
Recommend Reading
-
Dow Sounds the Alarm in Southeast Asia: Polymer MDI Prices Jump by $200/ton Amid Market Turbulence
-
Mitsubishi Chemical Announces Expansion of Advanced Carbon Fiber Production Capacity in Japan and the United States
-
The Crop Protection Patent Cliff Is Here
-
Glyphosate Becomes a Trade Fight
-
Covestro CEO: The EU Must Decide Which Industries to Protect, or Energy-Intensive Sectors Will Move Out
-
Business Society September 20, 2026 Ethanol Trend Analysis: Mild Correction
-
Business Society September 20, 2026 MTBE Trend Analysis: Volatile Consolidation
-
Key Reactions and Uses of Allene
-
Business Society September 20, 2026 Petroleum Coke Trend Analysis: Volatility
-
U.S. and China Open New High-Level Trade Talks on Tariffs, Critical Minerals and Pharma Investment